应用托法替布治疗类风湿关节炎的有效性及安全性

The efficacy and safety of the application of tofacitinib on rheumatoid arthritis

目的:探讨联合应用托法替布和改善病情抗风湿药(DMARDs)对治疗类风湿关节炎的有效性及安全性。方法:回顾性分析类风湿关节炎患者81例。患者在既往已正规使用DMARDs,后予联合应用托法替布和DMARDs。收集患者用药前和用药后关节疼痛评分、巴氏指数、炎症指标、肝功能等指标。记录并分析患者用药前后指标的变化情况。结果:患者联合用药后,关节疼痛评分下降,巴氏指数上升,炎症指标下降(P<0.05)。总蛋白、球蛋白用药后较用药前降低(P<0.05),其余指标无显著变化(P>0.05)。结论:联合应用托法替布和DMARDs可安全、有效地改善患者关节症状,提高患者日常生活活动能力,促进炎症指标的下降。托法替布对患者总蛋白及球蛋白的影响,尚需进一步随访观察。

Objective:To explore and discuss the efficacy and safety of combined application of tofacitinib and disease modifying antirheumatic drugs(DMARDs)on rheumatoid arthritis.Methods:The total of 81 patients who were suffered from rheumatoid arthritis were included.The patients had regularly used DMARDs before,and then were treated using the combined application of tofacitinib and DMARDs.We collected the joint pain score,Barthel Index,inflammatory markers,liver function,and other routine examination before and after the treatment.The changes of the data before and after the treatment were recorded and analysed.Results:After the combined application of tofacitinib and DMARDs,the joint pain score decreased,Barthel Index increased,and inflammatory markers decreased(P<0.05).The total protein and globulin decreased(P<0.05).No significant changes in other results(P>0.05).Conclusion:The combined application of tofacitinib and DMARDs can safely and effectively relieve patients'joint pain,improve patients'activities of daily living,and decrease inflammatory markers.While the effects of tofacitinib on total protein and globulin needs further follow-up and observation.